Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy-Reference-Cited by-同舟云学术

Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy

Published:2022-09-17 Issue:4 Volume:72 Page:865-879
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Okita Riki^ORCID,Mimura-Kimura Yuka,Kawamoto Nobutaka^ORCID,Yamamoto Naoki,Umeda Masashi,Okada Masanori,Inokawa Hidetoshi,Mimura Yusuke,Murakami Tomoyuki,Nakata Masao,Okabe Kazunori

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-022-03292-4.pdf

Reference48 articles.

1. Sugarbaker DJ, Flores RM, Jaklitsch MT et al (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54–63. https://doi.org/10.1016/s0022-5223(99)70469-1

2. Okada M, Kijima T, Aoe K et al (2019) Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin Cancer Res 25:5485–5492. https://doi.org/10.1158/1078-0432.CCR-19-0103

3. Baas P, Scherpereel A, Nowak AK et al (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397:375–386. https://doi.org/10.1016/S0140-6736(20)32714-8

4. Meirson T, Pentimalli F, Cerza F et al (2022) Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma. JAMA Netw Open 5:e221490. https://doi.org/10.1001/jamanetworkopen.2022.1490

5. Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S (2022) A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern. JTO Clin Res Rep 3:100280. https://doi.org/10.1016/j.jtocrr.2022.100280

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma;Scientific Reports;2024-07-10

2. Preoperative neutrophil-to-lymphocyte ratio correlates with PD-L1 expression in immune cells of patients with malignant pleural mesothelioma and predicts prognosis;Scientific Reports;2023-03-31

3. Editorial: Complexity of tumor microenvironment: A major culprit in cancer development;Frontiers in Endocrinology;2022-10-20